Literature DB >> 226565

Effects of the beta-adrenoceptor blocking agent sotalol on CNS: sleep, EEG, and psychophysiological parameters.

W Bender, W Greil, E Rüther, K Schnelle.   

Abstract

Sotalol (Sotalex), 320 or 960 mg, was administered to 12 healthy subjects daily for a period of four days in a double-blind trial over 11 days. The effects of sotalol on heart rate, blood pressure, EEG, subjective quality of sleep, polygraphically determined sleep pattern, and psychophysiological parameters such as psychomotor performance, memory, perception, vigilance, and general condition were studied and were related to dosage and plasma levels. Steady-state plasma levels of sotalol were reached within 24 hours after a single dose; 960 mg resulted in plasma levels three times higher than those reached with 320 mg, which indicates first-order linear absorption. The effects of sotalol on EEG, sleep, and performance in psychological tests were equivocal and do not yield evidence for CNS activity of sotalol.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 226565     DOI: 10.1002/j.1552-4604.1979.tb02515.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  5 in total

Review 1.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

2.  The tremorolytic action of beta-adrenoceptor blockers in essential, physiological and isoprenaline-induced tremor is mediated by beta-adrenoceptors located in a deep peripheral compartment.

Authors:  B Abila; J F Wilson; R W Marshall; A Richens
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

3.  [The EEG of patients with acute manic psychoses before, during and after treatment with high doses of d-propranolol and dl-propranolol (author's transl)].

Authors:  K Coulin; O Simon; H M Emrich; D von Zerssen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1982

4.  An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.

Authors:  P M McCaffrey; J G Riddell; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

Review 5.  Targeting modulation of noradrenalin release in the brain for amelioration of REMS loss-associated effects.

Authors:  Abhishek Singh; Birendra Nath Mallick
Journal:  J Transl Int Med       Date:  2015-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.